T
| T ProLymphocytic Leukemia panel at diagnosis ( 16-18 CD markers) |
| T(1:13) or PAX7-FKHR for Rhabdomyo sarcoma |
| t(1;13) PAX7/FOXO1A (FKHR) for Alveolar Rhabdomyosarcoma |
| t(1;13) PAX7/FOXO1A (FKHR) for Alveolar Rhabdomyosarcoma RT- PCR |
| t(1;14) SIL-TAL or del(1)SIL-TAL1 for T-ALL |
| t(1;19)TCF3-PBX1 or E2A-PBX1 /t(1;19) |
| t(11;14) IgH/CCND1 for Mantle cell Lymphoma |
| t(11;14) IgH/CCND1 or Cyclin D1/BCL1 /t(11;14) for Mantle cell lymphoma |
| t(11;14)(q13;q32) IGH/CCND1 for Mantle Cell Lymphoma (MCL) |
| t(11;18) API2/MLT for MALT Lymphoma |
| t(12;21) ETV6-RUNX1 or TEL-AML1 / t(12;21) for ALL (Qualitative) |
| t(12;21) ETV6-RUNX1 or TEL-AML1 / t(12;21) for ALL (Quantitative) |
| t(14;18) IgH/BCL2 (MBR) for Follicular Lymphoma |
| t(14;18) IgH/BCL2 (MBR) or IgH/BCL2 / t(14;18) for Follicular lymphoma |
| t(14;18) IgH/BCL2 (mcr) for Follicular Lymphoma |
| t(14;18) IgH/BCL2 (mcr) or IgH/BCL2 / t(14;18) for Follicular lymphoma |
| t(15;17) PML-RARA for AML-M3 and M3v (Quantitative) |
| t(15;17) PML-RARA for AML-M3 and M3v (Qualitative) |
| T(2:13) or PAX3-FKHR for Rhabdomyo sarcoma |
| t(2;13) PAX3/FOXO1A (FKHR) for Alveolar Rhabdomyosarcoma |
| t(2;13) PAX3/FOXO1A (FKHR) for Alveolar Rhabdomyosarcoma |
| t(4;11) MLL-AF4 for ALL |
| t(8;14) IgH/c-Myc for Burkitt Lymphoma / ALL- L3 |
| t(8;14)IgH/c-Myc & t(8;22) IgL/c-Myc & t(2;8) IgK/c-Myc for Burkitt Lymphoma -FISH |
| t(8;21)(q22;q22.1);RUNX1-RUNX1T1 or AML1-ETO/t(8;21) |
| T-ALL Body fluid panel ( 3-5 CD markers) |
| T-cell LGL Leukemia panel at diagnosis ( 16-18 CD markers) |
| TCR-γ (Gamma) gene rearrangement B ( Clonality Assay) |
| TCR-γ (Gamma) gene rearrangement A (Clonality Assay) |
| TCR-γ gene rearrangement for NHL |
| TCR-δ (Delta) gene rearrangement (Clonality Assay) |
| Thin prep |
| Thiopurine Meyhyl Transferase (TPMT) Toxicity to Azathioprin, 6 Mercaptopurine, 6 thioguanine |
| Toxoplasma gondii |
| Treponema pallidum |